Precision NanoSystems @ CLINAM 2017

Precision NanoSystems will be showcasing the benefits of its NanoAssemblr™ System and microfluidics technologies on booth #6 at this year’s European Foundation of Clinical Nanomedicine (CLINAM) conference and exhibition. Taking place in Basel, Switzerland, from the 7th to the 10th of May, this summit focuses on recent advances and current hurdles in the translation of nanomedicines from the research setting to the clinic.

The Precision NanoSystems team will be on hand throughout the conference to discuss the practical challenges of nanomedicine development, as well as participating in a number of other activities. In addition, company CEO and co-founder Dr James Taylor will be giving a presentation entitled Meeting the challenge with microfluidics: Enabling nanomedicine development from basic research to the clinic at 14:45 on Monday the 8th in Hall Sidney. Looking at the use of a microfluidic approach for the continuous manufacture of nanomedicines, he will be focusing on some of the new opportunities this technology offers in terms of reproducibility, scalability and the assembly of challenging particle types.

James commented: “Our company’s focus is on helping to accelerate this important area of medicine by developing technology that makes it easier for biopharmaceutical companies and academics to optimize and manufacture nanomedicines as drug products. We are happy to once again be supporting this important fixture in the calendar through the exhibition and our contributions to the scientific program, and look forward to discussing the latest breakthroughs and challenges with old friends and new faces alike.”

To learn more about Precision NanoSystems, visit

About Precision NanoSystems

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases. PNI’s NanoAssemblr™ Transfection Reagents use nanomedicine technology to deliver genetic materials in primary cells in vitro and in vivo, enabling disease researchers to easily study gene function in high-value models of disease. PNI’s proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of nanoparticle formulations for delivery of nucleic acids, drug molecules, and diagnostic agents to cells and tissues in the body. PNI sells its products to leading pharmaceutical and biotechnology companies, and leading academic institutions in over 20 countries worldwide.

Back to news